Usefulness of123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function

2004 ◽  
Vol 18 (7) ◽  
pp. 591-598 ◽  
Author(s):  
Shinichiro Fujimoto ◽  
Hideo Amano ◽  
Aritomo Inoue ◽  
Shuichi Ishida ◽  
Shohei Yamashdma ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Myocardial Scintigraphy ◽  
Cardiac Events

P104 Prognostic value of Circulating Amino Acids (AAs) in Patients with Idiopathic Dilated Cardiomyopathy (DCM)

2020 ◽  
Vol 41 (Supplement_1) ◽  
Author(s):  
M Wakasa ◽  
Y Kawai ◽  
K Kajinami
Keyword(s):  
Amino Acids ◽  
Cardiac Function ◽  
Cardiac Death ◽  
Negative Association ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Washout Rate ◽  
Lv Function ◽  
Reactive Oxygen Metabolites ◽  
Cardiac Events ◽  
Significant Positive Association

Abstract Backgrounds Circulating levels of some amino acids are significantly decreased in heart failure patients. However, relationship between their levels and cardiac function remains unclear. We therefore examined association between amino acid levels and cardiac function as prognostic predictor in DCM patients. Methods Consecutive 59 patients with DCM (M/F: 46/13, mean age: 59 years) were enrolled. We measured 25 kinds of plasma AA concentration, derivative of reactive oxygen metabolites (d-ROMs) as marker of oxidative stress, and washout rate of Tc-99m Sestamibi (WOR) as function of mitochondria and LVEF as LV function parameters. The occurrence of rehospitalization for cardiac events or cardiac death were followed during mean 1101 days (13-2626). Results Histidine, arginine and Fischer ratio (FR) showed a significant positive association with LVEF (p < 0.05). Threonine and asparagine showed a significant negative association with WOR (P < 0.05). Histidine and arginine showed a significant negative association with levels of d-ROMs (p < 0.05).Rehospitalization for cardiac events and cardiac death were recorded in 16 patients (27%) and 6 patients (10%), respectively. Kaplan-Meier curves analysis showed similar trend of rehospitalization in subjects with lower FR and those with higher values. However, cardiac death in subjects with lower FR was observed more frequently as compared to those with higher values (22.2% vs 5.3% p < 0.05). ConclusionsThe plasma FR could be a novel prognostic biomarker in DCM patients.

scholarly journals The Clinical Short-term Outcome of Atorvastatin and Trimetazidine Combination Treatment in Patients with Non-ST Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

2016 ◽  
Vol 8 ◽  
Author(s):  
Jiangyou Wang ◽  
Han Chen ◽  
Dan Song ◽  
Jian Peng ◽  
Xi Su
Keyword(s):  
Cardiac Function ◽  
Acute Coronary Syndromes ◽  
Coronary Intervention ◽  
Cardiac Events ◽  
Short Term ◽  
St Segment Elevation ◽  
St Segment ◽  
Adverse Cardiac Events ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

<p><strong>Background and Objectives: </strong>To investigate the effects of atorvastatin (ATV) and trimetazidine (TMZ) combination treatment in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention. <strong></strong></p><p><strong>Subjects and Methods: </strong>A total of 92 patients with NSTE-ACS were randomly divided into the pretreatment with ATV group (80mg 12h before PCI, with a further 20mg every day to 30th days after PCI, n=44) or the pretreatment with ATV (as the ATV group) and TMZ (60mg 30min before PCI, with a further 20mg tid to 30th days after PCI, n=48). Echocardiography was executed and plasma N-terminal pro brain natriuretic peptide (NT-pro-BNP) levels were measured just prior to the PCI and 30th days after PCI. The main end point was a 30-day incidence of major adverse cardiac events.</p><p><strong>Result: </strong>Major adverse cardiac events occurred in 9.1% of patients in the ATV group and 4.2% of those in the ATV+TMZ group (P=0.189). NT-pro-BNP of the two groups were decreased 30th days after PCI, however, NT-pro-BNP in the ATV+TMZ group were significantly lower than those in the ATV group (P&lt;0.05). Cardiac function in NSTE-ACS patients, as reflected by the increased LVEF, FS as well as decreased LVEDd (P&lt;0.05) in all groups at 30 days after intervention, but cardiac function parameters were more obviously improved in the group administered with ATV+TMZ (p&lt;0.05).</p><p><strong>Conclusion: </strong>Short-term pretreatment with the combination of ATV and TMZ administration prior to PCI can prominently decrease NT-pro-BNP and improve cardiac function compared to a single administration of the ATV. </p>

scholarly journals Myocardial Scintigraphy in the Evaluation of Cardiac Events in Patients without Typical Symptoms

2015 ◽  
Author(s):  
Paola Emanuela Poggio Smanio ◽  
Juliana Horie Silva ◽  
João Vitor Holtz ◽  
Leandro Ueda ◽  
Marilia Abreu ◽  
...  
Keyword(s):  
Myocardial Scintigraphy ◽  
Cardiac Events

scholarly journals Estrogens Mediate Cardiac Hypertrophy in a Stimulus-Dependent Manner

Endocrinology ◽  
2012 ◽  
Vol 153 (9) ◽  
pp. 4480-4490 ◽  
Author(s):  
Christopher D. Haines ◽  
Pamela A. Harvey ◽  
Leslie A. Leinwand
Keyword(s):  
Cardiac Hypertrophy ◽  
Cardiac Function ◽  
Estrogen Signaling ◽  
Dependent Manner ◽  
Cardiac Events ◽  
Established Risk Factor ◽  
Apparent Loss ◽  
Exercise Induced ◽  
Insight Into

The incidence of cardiac hypertrophy, an established risk factor for heart failure, is generally lower in women compared with men, but this advantage is lost after menopause. Although it is widely believed that estrogens are cardioprotective, there are contradictory reports, including increased cardiac events in postmenopausal women receiving estrogens and enhanced cardiac protection from ischemic injury in female mice without estrogens. We exposed aromatase knockout (ArKO) mice, which produce no estrogens, to both pathologic and physiologic stimuli. This model allows an investigation into the effects of a complete, chronic lack of estrogens in male and female hearts. At baseline, female ArKO mice had normal-sized hearts but decreased cardiac function and paradoxically increased phosphorylation of many progrowth kinases. When challenged with the pathological stimulus, isoproterenol, ArKO females developed 2-fold more hypertrophy than wild-type females. In contrast, exercise-induced physiological hypertrophy was unaffected by the absence of estrogens in either sex, although running performance was blunted in ArKO females. Thus, loss of estrogen signaling in females, but not males, impairs cardiac function and sensitizes the heart to pathological insults through up-regulation of multiple hypertrophic pathways. These findings provide insight into the apparent loss of cardioprotection after menopause and suggest that caution is warranted in the long-term use of aromatase inhibitors in the setting of breast cancer prevention.

scholarly journals Use of radiotelemetry to assess perinatal cardiac function in the ovine fetus and newborn

2017 ◽  
Vol 313 (6) ◽  
pp. R660-R668 ◽  
Author(s):  
A. Antolic ◽  
C. E. Wood ◽  
M. Keller-Wood
Keyword(s):  
Cardiac Function ◽  
New Technologies ◽  
Perinatal Period ◽  
Aortic Pressure ◽  
Late Gestation ◽  
Cardiac Conduction ◽  
Fetal Life ◽  
Cardiac Events ◽  
Fetal Ecg ◽  
Ovine Fetus

The late gestation fetal ECG (fECG) has traditionally been difficult to characterize due to the low fECG signal relative to high maternal noise. Although new technologies have improved the feasibility of its acquisition and separation, little is known about its development in late gestation, a period in which the fetal heart undergoes extensive maturational changes. Here, we describe a method for the chronic implantation of radiotelemetry devices into late gestation ovine fetuses to characterize parameters of the fECG following surgery, throughout late gestation, and in the perinatal period. We found no significant changes in mean aortic pressure (MAP), heart rate (HR), or ECG in the 5 days following implantation; however, HR decreased in the first 24 h following the end of surgery, with associated increases in RR, PR, and QRS intervals. Over the last 14 days of fetal life, fetal MAP significantly increased, and HR significantly decreased, as expected. MAP and HR increased as labor progressed. Although there were no significant changes over time in the ECG during late gestation, the duration of the PR interval initially decreased and then increased as birth approached. These results indicate that although critical maturational changes occur in the late gestation fetal myocardium, the mechanisms that control the cardiac conduction are relatively mature in late gestation. The study demonstrates that radiotelemetry can be successfully used to assess fetal cardiac function, in particular conduction, through the process of labor and delivery, and may therefore be a useful tool for study of peripartum cardiac events.

Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy

2007 ◽  
Vol 21 (7) ◽  
pp. 399-404 ◽  
Author(s):  
Aritomo Inoue ◽  
Shinichiro Fujimoto ◽  
Shohei Yamashina ◽  
Junichi Yamazaki
Keyword(s):  
Dilated Cardiomyopathy ◽  
Myocardial Scintigraphy ◽  
Cardiac Events

Dobutamine myocardial scintigraphy for the prediction of cardiac events after heart transplantation

2005 ◽  
Vol 26 (7) ◽  
pp. 607-612 ◽  
Author(s):  
Marcus Hacker ◽  
Andreas Tausig ◽  
Bernd Rom??ller ◽  
Xaver Hoyer ◽  
Volker Klauss ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Myocardial Scintigraphy ◽  
Cardiac Events

scholarly journals Global Longitudinal Strain Is Superior to Ejection Fraction for Long-Term Follow-up after Allogeneic Hematopoietic Stem Cell Transplantation

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1824-1824
Author(s):  
Marika Watanabe ◽  
Kimikazu Yakushijin ◽  
Hidekazu Tanaka ◽  
Ruri Chijiki ◽  
Miki Saeki ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Cardiac Dysfunction ◽  
Research Funding ◽  
Global Longitudinal Strain ◽  
Cardiac Events ◽  
Hematopoietic Stem ◽  
Allogeneic Hsct ◽  
Long Term Follow Up

Abstract Introduction: Recent advances in hematopoietic stem cell transplantation (HSCT) have improved the survival duration in patients who have undergone allogeneic HSCT, and accordingly, late-onset cardiovascular dysfunction is a major problem. Although the ejection fraction (EF) is the most useful parameter of cardiac function, heart failure with preserved EF (HFpEF), the prognosis of which is nearly the same as that of reduced EF, also exists. Recently, global longitudinal strain (GLS), which is more sensitive than the EF in detecting cardiac dysfunction, has been proposed as a new parameter of cardiac function determined using echocardiography. However, validity of GLS in monitoring patients who underwent allogeneic HSCT remains to be evaluated. Therefore, we evaluated long-term cardiac function in patients who had undergone allogeneic HSCT based on GLS and EF using echocardiography. Patients and Methods: We retrospectively reviewed the medical records of 85 patients (median age, 49 years; range, 17-69 years) with various hematological disorders who underwent allogeneic HSCT between April 2013 and March 2020 at Kobe University Hospital. The diagnoses included acute myeloid leukemia (AML; n = 37), acute lymphoblastic leukemia (n = 13), myelodysplastic syndromes (MDS; n = 5), malignant lymphoma (n = 22), and others (n = 8). Twenty-four patients received a transplant from a related donor (bone marrow, n = 10; peripheral blood, n = 4), while 61 received a transplant from an unrelated donor (bone marrow, n = 25; cord blood, n = 32; peripheral blood, n = 4). Graft-versus-host disease prophylaxis included cyclosporine-based (n = 14) or tacrolimus-based (n = 71). The conditioning regimens were myeloablative (n = 43) or reduced-intensity regimens (n = 42). We assessed the EF, GLS, and cardiac function using echocardiography at baseline (before transplantation) and 1, 3, and 5 year(s) after transplantation. The median cumulative anthracycline dose was 200 mg/m 2 (range; 0-786 mg/m 2). Patients with relapsed or refractory AML received more anthracycline doses, while patients with natural killer/T-cell lymphoma, aplastic anemia, and MDS did not receive anthracycline. We also investigated newly diagnosed cardiovascular events after HSCT. Cardiac events were defined as the development of hypertension, arrhythmia, and heart failure requiring medication or intervention. Further, we analyzed the effect of prescription of cardioprotective agents such as beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Results: The median follow-up duration in surviving patients was 1647 days (range; 88-2819). The overall survival rate at 5 years was 54.6%, and the causes of death were disease progression (n = 20), sepsis (n = 12), and renal failure (n = 3). None of the patients were hospitalized or died because of cardiac events. EF and GLS 1 year after transplantation were equivalent to those at baseline; however, GLS 3 years after transplantation was significantly decreased compared to that at baseline (P = 0.00006), although the EF did not change (Figure). The median decrease in GLS between baseline and 3 years after transplantation was 4.8% (range; -7.3% to 20.1%). Moreover, patients taking cardioprotective agents (n = 23) had a better GLS at 5 years than that at 3 years; median GLS changed from 10.9% at 3 years to 14.6% at 5 years, while median GLS of the other patients decreased from 11.6% to 8.9%. This suggests that cardioprotective drugs may improve cardiac function. Twenty-four patients (28%) developed newly diagnosed cardiovascular events, which occurred bimodally; 18 patients developed events within 1 year, and the others developed events beyond 4 years. The former tended to have hypertension or arrhythmia, whereas the latter had cardiac dysfunction. Patients who received more than 200 mg/m 2 of anthracycline tended to have slightly more cardiac events than those who received less than 200 mg/m 2 (P = 0.06). Conclusion: GLS after allogeneic HSCT significantly decreased, although the EF did not change. It is suggested that GLS is a more useful and sensitive parameter than the EF in patients undergoing long-term follow-up after allogeneic HSCT. Additionally, this study indicated that taking cardioprotective drugs may improve cardiac dysfunction after HSCT. Figure 1 Figure 1. Disclosures Yakushijin: Nippon Shinyaku: Honoraria; Jazz pharmaceuticals: Research Funding; Chugai pharmaceutical Co. Ltd.: Research Funding. Tanaka: AstraZeneca: Honoraria; Ono pharmaceutical: Honoraria. Matsuoka: Takeda Pharmaceutical Company: Research Funding; Sysmex: Research Funding. Minami: Bayer Yakuhin: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; DaiichiSankyo: Honoraria, Research Funding; Eisai: Honoraria, Research Funding; Kyowa-Kirin: Honoraria, Research Funding; Merck Serono: Honoraria, Research Funding; MSD: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Ono Pharmaceutical: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Takeda Pharmaceutical: Honoraria, Research Funding; Taiho Pharmaceutical: Honoraria, Research Funding; Eli Lilly: Honoraria, Research Funding; Asahi-Kasei Pharma: Research Funding; Astellas Pharma: Research Funding; Nippon Shinyaku: Research Funding; Yakult Honsha: Research Funding; CSL: Research Funding; Behring: Research Funding; Nippon Kayaku: Research Funding; Celgene: Honoraria; Ohtsuka Pharmaceutical: Honoraria; Shire Japan: Honoraria; Genomic Health: Honoraria; Abbvie: Honoraria.

Sign in / Sign up

Export Citation Format

Share Document